Payment overview · 2025
General Payments
$2,906.56
147 reported records · 30 companies
Healthcare provider profile · identity verified
Disha Patel, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · HARRINGTON PARK, NJ · NPI 1699919506
Verified facts
What the public records show
CMS Open Payments records show Disha Patel, M.D received $2,906.56 in general payments during 2025 across 147 reported records.
Amgen Inc. accounted for 13.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Sunosi, Xywav.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Sunosi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xywav by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $385.97 | 13.3% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $295.78 | 10.2% | 18 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $263.66 | 9.1% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $245.94 | 8.5% | 15 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $227.02 | 7.8% | 9 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $204.04 | 7.0% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $157.00 | 5.4% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$148.88 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $113.35 | 3.9% | 6 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $100.58 | 3.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.58 | 2.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.23 | 2.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $58.19 | 2.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $55.53 | 1.9% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $52.92 | 1.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.65 | 1.7% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $47.52 | 1.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.37 | 1.5% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $36.60 | 1.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.59 | 1.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.34 | 1.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.64 | 1.1% | 2 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $31.83 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.11 | 1.0% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.50 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.92 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.24 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.10 | 0.6% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $16.76 | 0.6% | 1 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $16.72 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,851.57 | 146 |
| Education | $54.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $296.16 | 22 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $296.16 | 22 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $263.66 | 13 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $227.02 | 9 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $204.04 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $191.86 | 11 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $148.88 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $102.01 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.98 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $100.98 | 7 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $100.58 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $89.81 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.65 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $79.58 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.53 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $58.19 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $55.53 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.08 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.34 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $52.92 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $47.52 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $35.18 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.07 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.34 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.11 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.66 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 115 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 86 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 85 | 30 |
| Alprazolam | Alprazolam | 68 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 16 |
| Losartan Potassium | Losartan Potassium | 31 | 12 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 21 | suppressed |
| Metformin Hcl | Metformin Hcl | 20 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Sunosi | Solriamfetol Hcl | 16 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lisinopril | Lisinopril | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,906.56 · 147 records | Amgen Inc. | AIRSENSE, Auvelity, CREON, Cologuard Collection Kit, ELIQUIS, EOHILIA, EVENITY, FARXIGA, Fluad, Flucelvax, INSPIRE, JARDIANCE, JATENZO, Kerendia, Korlym, LINZESS, LUMRYZ, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, RHINAER STYLUS, Rybelsus, SHINGRIX, SYMPLICITY G3, Sunosi, TRELEGY ELLIPTA, TREMFYA, TZIELD, UBRELVY, VIVAER STYLUS, VOQUEZNA, Veozah, WAKIX, Wegovy, XYWAV, Yorvipath, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error